Biohaven Pharmaceuticals to be acquired by Pfizer
The $11.6 billion agreement will see Pfizer acquire Biohaven’s calcitonin…
The $11.6 billion agreement will see Pfizer acquire Biohaven’s calcitonin gene-related peptide (CGRP) programmes, including migraine treatment rimegepant.